press release - Pappas Capital

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

SAN CARLOS, Calif.--10/23/25--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial in neurogenic orthostatic hypotension (nOH). nOH is a serious condition characterized by a sudden drop in blood pressure when a person moves from sitting to standing, or from a supine position to sitting, that leads to debilitating dizziness, fainting, falls, hospitalizations and cognitive impairment due to reduced blood flow to the brain.

0-Homepage Feature / 0-Megaphone / CuraSen Therapeutcis - 10/23/2025

Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDG

SAN CARLOS, Calif., September 3, 2025 -- Glycomine, Inc. announced today that the first participant has been dosed in the global Phase 2b study, called POLAR. This randomized placebo-controlled multi-center clinical trial is designed to assess the safety and efficacy of GLM101, an investigational mannose-1-phosphate substrate replacement therapy for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), a rare genetic disorder leading to serious neurological and multi-systemic impairments.

Glycomine - 09/04/2025

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

LA JOLLA, Calif., September 2, 2025 – Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.

Enlaza Therapeutics - 09/02/2025

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

Barcelona, Spain and Düsseldorf, Germany – 23 July 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, today announce that the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL®) has been submitted to the European Medicines Agency (EMA) for the treatment of paediatric and adult male patients with cerebral adrenoleukodystrophy (cALD). EMA has now validated the MAA file and it is under review by the Committee for Medicinal Products for Human Use (CHMP).

Minoryx - 07/23/2025

Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases

Barcelona, Spain, 17 July 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders today announces that it has secured a EUR 26.9m non-dilutive grant for the development of its LERI4CNS project, which will validate leriglitazone for treating potentially lethal rare diseases affecting the CNS. The grant was given as part of the pan-European project “Important Project of Common European Interest (‘IPCEI') Med4Cure”, of which Minoryx Therapeutics is an Associated Member.

Minoryx - 07/17/2025

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPVAssociated Oropharyngeal Squamous Cell Carcinoma

SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck.” The poster will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois.

BioAtla - 06/02/2025

Aktis Oncology Initiates Phase 1B Clinical Trial of its Nectin-4-Targeting Radiopharmaceutical Product Candidate, AKY-1189, Across Multiple Tumor Types

BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced that it has initiated clinical development of AKY-1189 in its Phase 1b clinical trial for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC), triple negative breast cancer (TNBC) and potentially other Nectin-4 expressing tumors.

Aktis Oncology - 05/28/2025

Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG

SAN CARLOS, Calif.--April 16, 2025--Glycomine, Inc., a biotechnology company focused on developing transformative new therapies for orphan diseases, today announced a $115 million Series C financing to advance its lead candidate, GLM101, into a Phase 2b clinical trial. The financing was led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures.

Glycomine - 04/16/2025

Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial

BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series A financing that included participation from five new investors – Eli Lilly and Company, Biovision Ventures, Pappas Capital, Hengdian Group Capital (HgC), and The Leukemia & Lymphoma Society Therapy Acceleration Program® – as well as continued support from existing Solu investors Longwood Fund, DCVC Bio, Santé Ventures, Astellas Venture Management, and Alexandria Venture Investments. The company also announced initiation of treatment of the first patient in its first-in-human Phase 1 clinical trial evaluating STX-0712 in patients with resistant/refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies.

Solu Therapeutics - 04/10/2025

Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study)

Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study has been dosed with leriglitazone. TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.

Minoryx - 03/07/2025

Investor Login

CuraSen Therapeutics Doses First Patient with…